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Background: Acute pancreatitis (AP) is one of themost common cause of hospitalization
among gastrointestinal diseases worldwide. Although most of the cases are mild,
approximately 10–20% of patients develop a severe course of disease with higher
mortality rate. Scoring systems consider age as a risk factor of mortality and severity
(BISAP; >60 years, JPN>70 years, RANSON; >55 years, APACHE II >45 years). If there
is a correlation between aging and the clinical features of AP, how does age influence
mortality and severity?
Aim: This study aimed to systematically review the effects of aging on AP.
Methods: A comprehensive systematic literature search was conducted in the
Embase, Cochrane, and Pubmed databases. A meta-analysis was performed using the
preferred reporting items for systematic review and meta-analysis statement (PRISMA).
A total of 1,100 articles were found. After removing duplicates and articles containing
insufficient or irrelevant data, 33 publications involving 194,702 AP patients were
analyzed. Seven age categories were determined and several mathematical models,
including conventional mathematical methods (linear regression), meta-analyses (random
effect model and heterogeneity tests), meta-regression, funnel plot and Egger’s test
for publication bias were performed. Quality assessment was conducted using the
modified Newcastle–Ottawa scale. The meta-analysis was registered in the PROSPERO
database (CRD42017079253).
Results: Aging greatly influences the outcome of AP. There was a low severe AP
incidence in patients under 30 (1.6%); however, the incidence of severe AP showed
a continuous, linear increase between 20 and 70 (0.193%/year) of up to 9.6%. The
mortality rate was 0.9% in patients under 20 and demonstrated a continuous linear
elevation until 59, however from this age the mortality rate started elevating with 9 times
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higher rate until the age of 70. The mortality rate between 20 and 59 grew 0.086%/year
and 0.765%/year between 59 and 70. Overall, patients above 70 had a 19 times higher
mortality rate than patients under 20. The mortality rate rising with age was confirmed
by meta-regression (coefficient: 0.037 CI: 0.006–0.068, p = 0.022; adjusted r2: 13.8%),
and severity also (coefficient: 0.035 CI: 0.019–0.052, p < 0.001; adjusted r2: 31.6%).
Conclusion: Our analysis shows a likelihood of severe pancreatitis, as well as,
pancreatitis-associated mortality is more common with advanced age. Importantly, the
rapid elevation of mortality above the age of 59 suggests the involvement of additional
deteriorating factors such as co-morbidity in elderly.
Keywords: acute pancreatitis, aging, mortality, severity, co-morbidity
INTRODUCTION
Rationale
Life expectancy has dramatically risen by 16 years (from 55.4
years to 71.4 years) in the last half century, causing a number
of changes and challenges to economies and healthcare systems
(Figure 1). Needless to say, healthcare professionals should focus
more intensively on the effects of aging on the course and
outcome of diseases.
Acute pancreatitis (AP) is one of the most challenging
gastrointestinal disorders: (1) its development is not fully
understood (Sahin-Toth and Hegyi, 2017) and it has no specific
therapy (Hegyi and Petersen, 2013); (2) its incidence rate
is continuously increasing (Peery et al., 2015); and (3) it
has an unacceptably high mortality (Parniczky et al., 2016).
Unfortunately, gastrointestinal scientists are devoting ever less
attention to AP (Szentesi et al., 2016). One of the best examples of
this is that mathematical analysis on the effects of aging on many
diseases, such as neurophysiological and liver disorders, have
been performed (Mizuguchi et al., 2015) but no systematically
collected information is available on AP.
Objectives
Age is used as a predictive marker in different scoring systems
for AP (Table 1). These scoring systems show a great variety in
the age group: in the (i) Bedside Index for Severity in Acute
Pancreatitis score (BISAP) (Wu et al., 2008), the topmost risk of
age is above 60; (ii) in BALI (BUN, Age, LDH, IL-6), it is over 65
(Spitzer et al., 2006); (iii) in the Simplified Acute Physiology Score
(SAPS II), it is >40 (Legall et al., 1993); (iv) in Ranson score, it
is above 55 (Blamey et al., 1984); (v) in Acute Physiology and
Chronic Health Evaluation (APACHE II), it is over 45 (Wagner
and Draper, 1984); and (vi) in the Japanese Severity Score (JNP),
it is >70 (Hirota et al., 2006). The wide range of age limits
suggests that a low number of patients, a selection bias and/or
a mathematical inaccuracy could have occurred.
Abbreviations: A70, above 70 years; ABP, acute biliary pancreatitis; AP, acute
pancreatitis; APACHE II, Acute Physiology and Chronic Health Evaluation; BALI,
BUN, Age, LDH, IL-6; BISAP, Bedside Index for Severity in Acute Pancreatitis
score; CI, confidence interval; ES, effect sizes; IQR, interquartile range; JNP,
Japanese Severity Score; OR, odd’s ratio; U20, under 20 years; PRISMA, preferred
reporting items for systematic review and meta-analysis statement; SAPS II,
Simplified Acute Physiology Score; SD, standard deviation.
Research Question
In order to minimize these distorting factors, we aimed to (i)
comprehensively search and select articles in which all AP cases
have been included and (ii) use several mathematical models to
understand the effects of aging on the outcome of AP.
METHODS
Study Design, Participants, Interventions,
Comparators
The meta-analysis was performed using the preferred reporting
items for systematic review and meta-analysis statement
(PRISMA) (Moher et al., 2009). We used the classical PICO
format to form a question applicable for search in databases: P:
acute pancreatitis; I and C: different age categories [under 20
(U20), 20–29, 30–39, 40–49, 50–59, 60–69, and above 70 (A70)];
O: mortality and severity. In order to provide the highest level
of quality, the meta-analysis was registered with the PROSPERO
registry (CRD42017079253).
Search Strategy
A searchwas performed in three databases (Embase, PubMed and
Cochrane) in January 2017 using the following terms: PubMed:
{acute[All Fields] AND (“pancreatitis“[MeSH Terms] OR
“pancreatitis”[All Fields])} AND {cohort[All Fields] OR (“clinical
trial”[Publication Type] OR “clinical trials as topic”[MeSH
FIGURE 1 | Life expectancy at birth. There is a steadily rising average life
expectancy at birth. It has dramatically risen by 16 years (from 55.4 to 71.4 y)
in the last half century. Data sources: between 1960 and 1999, World Bank;
between 2000–2015, WHO.
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TABLE 1 | Characteristics of the scoring systems.
Score system Publ. (year) Outcome Time at measurement Age cutoff Patient enrolment LEB Age
Med. Mean
Ranson 1974 Severity 48 h 55 1971–1975 60.12 42 50
APACHE II 1982 Severity 24 h 45 1979–1981 62.9 –
SASP II 1993 Mortality last 24 h 40 1991 65.6 57.2
JPN 2002 Severity – 70 1995–1998 66.75 –
BALI 2006 Mortality 48 h 65 – – 61 ± 16
BISAP 2008 Morality 24 h 60 2000–2001 66.55 53
There is a slight elevation in the age of enrolled patients and cut-off values (LEB: Life expectancy at birth). Ranson (Blamey et al., 1984); APACHEII–Acute physiology and chronic health
evaluation (Wagner and Draper, 1984); SAPS II–Simplified Acute Physiology Score (Legall et al., 1993); JNP–Japanese Severity Score (Hirota et al., 2006); BALI–BUN, Age, LDH, IL-6
(Spitzer et al., 2006); BISAP–Bedside Index for Severity in Acute Pancreatitis (Wu et al., 2008).
Terms] OR “clinical trial”[All Fields])} AND (“Age”[Journal]
OR “age”[All Fields] OR “Age (Omaha)”[Journal] OR “age”[All
Fields] OR “Age (Dordr)”[Journal] OR “age”[All Fields] OR
“Adv Genet Eng”[Journal] OR “age”[All Fields]) Embase: acute
pancreatitis and (cohort or clinical trial) and age; and Cochrane:
acute AND pancreatitis AND (cohort OR clinical) AND trial
AND age.
Data Sources, Study Selection, and Data
Extraction
Two independent authors read the articles for eligibility (age
data from cohort and pilot studies) (A-ML, KM). The flow
diagram recommended by the PRISMA guidelines shows the
article selection procedure (Figure 2) (Moher et al., 2009). When
conflicts arose, a third participant (PH) made the decision. Two
authors collected data in an Excel file (Microsoft Corporation,
Redmond, WA98052, USA) according to age (mean, median,
range, standard deviation (SD) and interquartile range (IQR),
where possible), study type, severity, mortality, and notes
(A-ML, KM).
Data Analysis
All meta-analytic calculations were performed with STATA
software Version 11 (Stata Corporation, College Station, TX,
USA). In our meta-analysis, the pooled effect sizes (ES) were the
event rates with a 95% confidence interval (CI) for all outcomes.
The random effect model by DerSimonian and Laird was used
in all cases (DerSimonian and Laird, 1986). Heterogeneity was
tested using Cochrane’s Q and the I2 statistics. I2 statistics
represent the percentage of effect size heterogeneity, which
cannot be explained by random chance, but by other factors. I2-
values of 25, 50, and 75% corresponded to low, moderate and
high degrees of heterogeneity, based on the Cochrane handbook
(Higgins, 2011). If the Q test is significant, it implies that the
heterogeneity among effect sizes reported in the observed studies
is greater than could be explained only by random error. We
considered the Q test significant if p < 0.1. The forest plot was
evaluated to represent the data. Publication bias was examined by
visual inspection as asymmetry in the funnel plot and Egger’s test
(Sterne et al., 2001). A significant test result (p < 0.1) indicates
the presence of bias.
A meta-regression was used to consider the effect of aging on
mortality and severity. In both cases, we tested the hypothesis
that all coefficients are zero. The results are provided as regression
coefficients, 95% CIs, p-values and the explained variances of the
models (R2 analogs).
A conventional regression analysis was also performed to
confirm the results of the meta-regression. In this case, we used
the pooled event rates from the subgroup analyses and themiddle
of the age subgroups as independent variables. We used the IBM
SPSS Statistics software for these calculations (IBM Corporation,
Armonk, New York, USA, Version 24).
Quality Assessment
The quality of the articles was assessed by 3 main categories
recommended by the modified Newcastle-Ottawa scale (Table 2,
Supplementary Figure 1).
RESULTS
Flow Diagram of Studies Retrieved for the
Review, Study Selection, and
Characteristics
Our search yielded 1,100 articles (704, 379, and 17 in
Embase, PubMed, and Cochrane, respectively) (Figure 2). Eleven
additional articles were found with potential data eligibility for
the meta-analysis in the references of the primarily selected
articles. After excluding duplicates and irrelevant articles, a
total of 33 articles involving 194,702 patients met the inclusion
criteria (Table 2).
Synthetized Findings
Severity
A total of 23 studies with 22,451 patients were suitable
for analyzing severity (Tables 2, 3) (Abou-Assi et al., 2002;
Gürleyik et al., 2005; Muller et al., 2006; De Waele et al.,
2007; Knoepfli et al., 2007; Uomo et al., 2007; Radenkovic
et al., 2009; Gomez Beltran et al., 2013; Gornik et al., 2013;
Nijmeijer et al., 2013; Albulushi et al., 2014; de-Madaria
et al., 2014; Zuidema et al., 2014; Ho et al., 2015; Ocampo
et al., 2015; Wang et al., 2015; Yue et al., 2015; Karpavicius
et al., 2016; Mole et al., 2016; Parniczky et al., 2016; Rashidi
and Røkke, 2016; Weitz et al., 2016; Zhang et al., 2016).
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FIGURE 2 | PRISMA flow diagram. The diagram for the study selection for this meta-analysis is based on the PRISMA-recommended flow chart (Moher et al., 2009).
Two thousand Four Hundred Eighty Nine severe cases were
found divided into seven age groups with a low severity rate
under 30 years. There was a low incidence severe AP rate in
patients under 30 and rose continuously between ages 30 and
70 (Table 3).
Firstly, a meta-regression was performed to investigate the
relationship between age and severity (Figure 3). The number
of patients in each age group category was extremely diverse
(between 24 and 11,933); however, a significant relationship was
detected (coefficient: 0.035 CI: 0.019–0.052, p < 0.001; adjusted
r2: 31.6%). A conventional regression analysis was also performed
showing a linear increase (0.193%/year) from ages U20 to
A70 (Figure 4).
This continuous elevation was also confirmed by forest plot
(Figure 5). There was 1 severe AP U20: 4.2% (1/24; pooled
event rate: 0.042 CI: −0.077–0.161); 20–29: 0% (0/36; pooled
event rate: 0.014 CI: 0.077–0.104); 30–39: 6.7% (5/75; pooled
event rate: 0.067 CI: −0.005–0.128); 40–49: 9.2% (726/7882;
pooled event rate: 0.109 CI: 0.046–0.172); 50–59: 11.3% (1352/11
933; pooled event rate: 0.201 CI: 0.158–0.245); 60–69: 16.6%
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TABLE 2 | The modified Newcastle–Ottawa quality assessment scale.
Study Sample size Severe case Mortality Study type Modified Newcastle-Ottawa quality assessment scale
Selection Comparability Outcome Sum
S1 S2 S3 S4 C1 O1.1 O1.2 O2 O3
Abou-Assi et al., 2002 156 5 14 Prospective 1 1 0 1 1 0 1 1 1 7
Albulushi et al., 2014 174 14 0 Retrospective 1 1 0 0 1 0 1 1 1 6
Gomez Beltran et al., 2013 24 1 0 Retrospective 1 1 1 1 1 0 1 1 1 8
de-Madaria et al., 2014 403 28 17 Prospective 1 1 1 1 0 1 0 1 1 7
Dombernowsky et al., 2016 359 nd 13 Retrospective 1 1 1 1 1 0 1 1 1 8
Gompertz et al., 2012 128 nd 2 Retrospective 1 1 1 1 0 0 0 1 1 6
Gompertz et al., 2013 1367 nd 115 Retrospective 1 1 1 1 0 1 0 1 1 7
Gonzalez-Gonzalez et al.,
2012
605 nd 30 Prospective 1 1 1 1 1 1 1 1 1 9
Gornik et al., 2013 1058 210 41 Prospective 1 1 0 1 0 0 1 1 1 6
Gürleyik et al., 2005 55 13 1 Prospective 1 1 1 1 1 1 1 1 1 9
Karpavicius et al., 2016 102 20 5 Prospective 1 1 1 1 0 1 0 1 1 7
Knoepfli et al., 2007 310 63 8 Prospective 1 1 1 1 1 1 0 1 1 8
Lautz et al., 2011 211 nd 0 Retrospective 1 1 1 1 0 1 1 1 1 8
Milheiro et al., 1995 91 nd 10 Retrospective 1 1 0 1 0 0 0 1 1 5
Mole et al., 2016 2053 390 102 Retrospective 1 1 0 1 0 0 1 1 1 6
Muller et al., 2006 109 66 8 Prospective 1 1 1 1 1 1 1 1 1 9
Nijmeijer et al., 2013 622 119 20 Prospective 1 1 0 1 0 0 0 1 1 5
Ocampo et al., 2015 854 140 nd Prospective 1 1 0 1 1 0 1 1 1 7
Pant et al., 2014 55012 nd 509 Retrospective 1 1 0 0 0 0 0 1 1 4
Parniczky et al., 2016 600 53 17 Prospective 1 1 1 1 1 1 1 1 1 9
Radenkovic et al., 2009 91 24 8 Prospective 1 1 1 1 0 1 0 1 1 7
Rashidi and Røkke, 2016 670 43 37 Prosp and Retrosp 1 1 1 1 1 1 0 1 1 8
Spanier et al., 2013 78257 nd 9515 Retrospective 1 1 0 1 1 0 1 1 1 7
Uomo et al., 2007 1173 167 36 Prospective 1 1 1 1 0 1 1 1 1 8
De Waele et al., 2007 40 14 6 Retrospective 1 1 1 1 0 1 0 1 1 7
Wang et al., 2015 120 31 13 Retrospective 1 1 0 1 0 0 0 1 1 5
Ho et al., 2015 12284 765 nd Retrospective 0 1 0 1 0 0 0 1 1 4
Weitz et al., 2016 346 21 12 Retrospective 1 1 1 1 0 1 1 1 1 8
Wu et al., 2008 36178 nd 569 Retrospective 1 1 0 0 0 0 0 1 1 4
Yeung et al., 1996 43 nd 1 Retrospective 1 1 0 0 1 0 1 1 1 6
Yue et al., 2015 169 68 nd Prospective 1 1 0 1 0 0 0 1 1 5
Zhang et al., 2016 974 223 58 Retrospective 1 1 1 1 0 1 1 1 1 8
Zuidema et al., 2014 64 11 3 Prospective 1 1 0 1 0 0 0 1 1 5
Ranks in three categories (green-1: low risk; red-0: high risk, yellow-0: unclear risk) are shown. S1, non-selected etiology AP; S2, all participants have an AP diagnosis; S3, AP diagnosis is
confirmed using the latest guidelines; S4, non-selected severity cases. C1: comparability defined by exact age ranges in years. O1.1, severity assigned according to the latest guidelines;
O1.2, described mortality (in-hospital and pancreas-related); O2–O3, adequate follow-up for outcome occurrence morality and severity.
(390/2344; pooled event rate: 0.157 CI: 0.110–0.203); A70: 9.6%
(15/157; pooled event rate: 0.096 CI: 0.049–0.143). In sum, 11.1%
(2489/22 451).
Publication bias was tested by inspection of funnel plot and
Egger’s test (CI: 1.961–6.728; p = 0.001). The visible asymmetry
(plots are mostly concentrated to the right side) is most probably
due to the fact that authors mostly present data with high volume
examinations (Supplementary Figure 2).
The cut-off values in sorting articles to U20 and A20, U30 and
A30, U40 and A40, U50 and A50, U60 and A60, andU70 and A70
(Supplementary Figures 3–8) resulted in significant differences
considering three comparison, respectively (U30 vs. A30 p =
0.036; U40 vs. A40 p= 0.009; U50 vs. A50 p= 0.021) (Figure 6).
In addition, we performed several sub-group analysis in
order to decrease the heterogeneity in our study. Firstly,
we used articles only where severity was assessed by the
Atlanta or the revised Atlanta classification. This additional
analysis could largely decrease the heterogeneity [I2 = 40–
49: 0%, 50–59:96.9%, 60–69:86.6% (Supplementary Figure 9)].
Secondly, we excluded the low quality (NOS 4 and 5) studies
from the analysis. This analysis also could improve the
heterogenity [(I2 = 40–49: 96.3%, 50–59:96.5%, 60–69:86.6%
(Supplementary Figure 10)].
And finally, we excluded studies from the analysis where
age ranges might overlap between the groups because of
given age ranges. We could also successfully decrease the
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TABLE 3 | Data of patient’s number and severe cases in age groups.
Age Severe AP Patient no. %
U20 1 24 4.2
20–29 0 36 0.0
30–39 5 75 6.7
40–49 726 7882 9.2
50–59 1352 11933 11.3
60–69 390 2344 16.6
A70 15 157 9.6
Sum 2489 22451 11.1
There was only one severe AP in patients under 30; however, the incidence of severe AP
rose continuously between ages 30 and 70.
heterogeneity [(I2 = 40–49: 98%, 50–59:97.1%, 60–69:86.6%
(Supplementary Figure 11)].
Importantly, none of them modified the outcome of the study
which decrease the overall limitations of our results.
Mortality
Thirty studies involving 181,395 subjects contained data on
mortality (Milheiro et al., 1995; Yeung et al., 1996; Abou-Assi
et al., 2002; Gürleyik et al., 2005; Muller et al., 2006; De Waele
et al., 2007; Knoepfli et al., 2007; Uomo et al., 2007; Wu et al.,
2008; Radenkovic et al., 2009; Lautz et al., 2011; Gompertz et al.,
2012, 2013; Gonzalez-Gonzalez et al., 2012; Gomez Beltran et al.,
2013; Gornik et al., 2013; Nijmeijer et al., 2013; Spanier et al.,
2013; Albulushi et al., 2014; de-Madaria et al., 2014; Pant et al.,
2014; Zuidema et al., 2014; Wang et al., 2015; Dombernowsky
et al., 2016; Karpavicius et al., 2016; Mole et al., 2016; Parniczky
et al., 2016; Rashidi and Røkke, 2016; Weitz et al., 2016; Zhang
et al., 2016) (Tables 2, 4). Eleven thousand one hundred and
seventy deceased cases were found in the seven age groups with
the highest rates in groups 40–49 and A60 (Table 4). Considering
that a severe course of AP increases the risk for mortality,
we expected a similar regression to severity (Figure 4). The
mortality rate was 0.9% in patients under 20 and demonstrated
a continuous, linear elevation until 59, however from this age
the mortality rate started elevating with 9 times higher rate until
the age of 70 (Figure 7). The mortality rate grew 0.086%/year
between ages 20 and 59 and 0.765%/year between 59 and 70
(Figure 7). Overall, patients above 70 had a mortality rate 19
times higher than those under 20 (Table 4). The mortality rate
rising with age was also confirmed by forest plot, showing a
clear elevation from pediatric to elderly patients: U20: 0.9%
(510/55 290; pooled event rate: 0.009 CI: 0.008–0.010); 20–29:
2.6% (5/1912; pooled event rate: 0.009 CI: −0.011–0.029); 30–
39: 1.2% (139/11 527; pooled event rate: 0.012 CI: 0.010–0.014);
40–49: 6.7% (202/3002; pooled event rate: 0.052 CI: 0.025–0.079);
50–59: 2% (838/41 634; pooled event rate: 0.045 CI: 0.032–0.057);
60–69: 8.5% (2153/25 452; pooled event rate: 0.052 CI: 0.015–
0.088); and A70: 17.3% (7312/42 322; pooled event rate: 0.112 CI:
0.007–0.217) (Figure 8). In summary, 6.2% (11 170/181 395).
A meta-regression analysis on mortality showed a significant
difference (coefficient: 0.037 CI: 0.006–0.068, p= 0.022; adjusted
r2: 13.8%, Figure 9). Publication bias was tested by funnel plot
and Egger’s test (CI: −0.901–9.234; p = 0.104) and showed
FIGURE 3 | Meta-regression of severity. The figure shows 29 data from 23
reports where x = age (mean), y = logit event rate: ln[p/(1-p)], and circle
diameters show the weight of each study based on the random effect model.
The meta-regression shows a significant (p < 0.001) relationship between age
and severity (r2 = 31.6), therefore the risk for developing severe cases is
elevated by aging.
FIGURE 4 | Conventional regression of severity. The conventional regression,
which is independent of distortion from diverse numbers of patients, shows a
linear rise (0.193%/year) in severity from young to old age.
mild asymmetry, but based on Egger’s test publication bias was
unlikely (Supplementary Figure 12).
Forest plot analyses comparing U20 to A20, U30 to A30,
U40 to A40 and U50 vs. A50 showed significant differences,
respectively (U20 vs. A20 p < 0.001; U30 vs. A30 p = 0.001; U40
vs. A40 p < 0.001; U50 vs. A50 p= 0.018; U60 vs. A60 p= 0.028,
and U70 vs. A70 p = 0.038) (Supplementary Figures 13–18).
Forest plot results are summarized in Figure 10.
We excluded the low quality (NOS 4 and 5) studies from
the analysis to lower the heterogeneity [I2 = 40–49: 96.3%,
50–59:96.5%, 60–69:86.6% (Supplementary Figure 19)].
Risk of Bias and Quality Assessment
The risk of bias was examined by funnel plot and
Egger’s test (see above severity and mortality). The
quality of the included articles were assessed by using
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FIGURE 5 | Forest plot of studies evaluating severity in acute pancreatitis in age groups. Full diamonds show the weighted event rates for studies, respectively, line
represents the 95% confidence interval (CI), and empty diamonds show the pooled results of severe cases with a steadily rising frequency from young to older age.
Wideness of the empty diamond represents the confidence limits. Under 40 there is a slight elevation concerning severe cases, from 40 to 60 severity rates differs in
the studies, then A60 remains stable.
the modified Newcastle–Ottawa scale as described earlier
(Deeks et al., 2003; Mata et al., 2015; Rotenstein et al., 2016).
Two independent investigators have evaluated the
articles and classified using a clear guidance described in
Supplementary Figure 1. The following three main categories
were applied: (i) selection of study groups (including four
subgroups: S1: non-selected etiology AP; S2: all participants have
an AP diagnosis; S3: AP diagnosis is confirmed using the latest
guidelines; S4: non-selected severity cases); (ii) comparability
of the groups (C1: comparability defined by exact age ranges in
years); and (iii) outcome of interest (including four subgroups:
O1.1: severity assigned by the latest guidelines; O1.2 described
mortality (in-hospital and pancreas-related); and O2–O3:
adequate follow-up for outcome occurrence, morality and
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FIGURE 6 | Forest plot results for cut-off values for severity. Summary table of pooled effect with CI and significance levels to detect cut off value. Concerning
mortality all comparisons were significant, however examining severity only three. Explanation might be that in young ages there is a low event rate, in middle age
groups there is a higher proportion therefore the difference is equalized leading to a non-significant difference. The same occur in the aged vs. middle aged groups.
TABLE 4 | Data of patient’s number and deceased cases in age groups.
Age Fatal event Patient no. %
U20 510 55290 0.9
20–29 5 1912 0.26
30–39 139 11527 1.2
40–49 202 3002 6.7
50–59 838 41790 2.0
60–69 2157 25496 8.5
A70 7319 42378 17.3
Sum 11170 181395 6.2
The incidence of severe AP rose continuously between ages 30 and 70.
FIGURE 7 | Conventional regression of mortality. The conventional regression
shows a linear elevation until 59, however from this age the mortality rate
started elevating with 9 times higher rate until the age of 70.
severity). Each item was marked: green-1: low risk; red-0: high
risk and yellow-0: unclear risk of bias. A total of 9 points was the
maximum that could be assigned (Table 2) (Milheiro et al., 1995;
Yeung et al., 1996; Abou-Assi et al., 2002; Gürleyik et al., 2005;
Muller et al., 2006; De Waele et al., 2007; Knoepfli et al., 2007;
Uomo et al., 2007; Wu et al., 2008; Radenkovic et al., 2009; Lautz
et al., 2011; Gompertz et al., 2012, 2013; Gonzalez-Gonzalez
et al., 2012; Gomez Beltran et al., 2013; Gornik et al., 2013;
Nijmeijer et al., 2013; Spanier et al., 2013; Albulushi et al., 2014;
de-Madaria et al., 2014; Pant et al., 2014; Zuidema et al., 2014;
Ho et al., 2015; Ocampo et al., 2015; Wang et al., 2015; Yue et al.,
2015; Dombernowsky et al., 2016; Karpavicius et al., 2016; Mole
et al., 2016; Parniczky et al., 2016; Rashidi and Røkke, 2016;
Weitz et al., 2016; Zhang et al., 2016).
Whenever different points were given by the investigators a
third member of the team made the final decision.
DISCUSSION
Summary of Main Findings
Here we provide the first detailed meta-analysis on the effects of
aging on AP. Aging has been demonstrated to play an important
role in AP; however, due to the lack of detailed mathematical
analysis, there is a great difference between the cut-off values used
in predictive scoring systems (Blamey et al., 1984; Wagner and
Draper, 1984; Legall et al., 1993; Hirota et al., 2006; Spitzer et al.,
2006; Wu et al., 2008).
With regard to severity, unfortunately we only have two
articles in which severity was one of the outcome parameters in
youth. In one of these studies, Párniczky et al. found no severe
cases in the 36 patients under 30 years of age (Parniczky et al.,
2016). Similarly, Beltrán et al. found only a single severe case in
cohort of 24 patients suggesting a low incidence rate of severe AP
in youth (Gomez Beltran et al., 2013). Our situation was far easier
regards mortality as data from large nationwide cohorts were
available. In a large epidemiology study involving 55,012 patients
under 20 years in the USA, Pant et al. showed that mortality
is only 0.92% (Pant et al., 2014). Others have also described
low mortality in smaller cohorts. Lautz et al. found 0% (0/211
patients) mortality under 20 years, while Yeung et al. reported
2.33% (1/43 patients) (Yeung et al., 1996; Lautz et al., 2011). In
contrast, no mortality was found among 1,720 patients between
the ages of 20 and 29 in a Hungarian and a Dutch cohort (Spanier
et al., 2013; Parniczky et al., 2016). Middle-aged patients (30–59
y) had a mortality rate more than two times higher (Abou-Assi
et al., 2002; Gürleyik et al., 2005; Muller et al., 2006; De Waele
et al., 2007; Knoepfli et al., 2007; Wu et al., 2008; Radenkovic
et al., 2009; Nijmeijer et al., 2013; Spanier et al., 2013; Albulushi
et al., 2014; de-Madaria et al., 2014; Zuidema et al., 2014; Wang
et al., 2015; Dombernowsky et al., 2016; Karpavicius et al., 2016;
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FIGURE 8 | Forest plot of studies evaluating mortality in acute pancreatitis. Full diamonds show the weighted event rates for studies, respectively, line represents the
95% confidence interval (CI), and empty diamonds show the pooled results of mortality with a steadily rising frequency from young to older age. Wideness of the
empty diamond represents the confidence limits. The diamonds show a steadily rising frequency in mortality from youth to old age.
Mole et al., 2016; Parniczky et al., 2016; Rashidi and Røkke, 2016;
Weitz et al., 2016; Zhang et al., 2016).
Our second main observation was that up until 59 years
(this cut-off value was mathematically calculated), both severity
and mortality rise linearly (Figures 4, 7). The rate of severity
increases 0.193%/year, and mortality grows 0.086%/year. It
has been documented that almost all death cases come from
the severe AP group; therefore, we can assume that although
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the number of severe cases rises every year, the risk for
mortality in severe AP remains constant at around 20%
(Parniczky et al., 2016).
Thirdly, we found that above 59 years the mortality rate
rapidly increases; meanwhile, the rate of severe pancreatitis
follows the earlier, slightly elevated pattern (Figures 4, 7). These
data clearly suggest that additional factors which are lacking or
rare below 59 years also affect mortality in AP. One of the best
candidates responsible for the increased elevation of mortality
in elderly is definitely co-morbidity. It has been shown that the
burden of co-morbidities increases with age (Vasilopoulos et al.,
2014; Murata et al., 2015). In addition, it has been also reported
that the outcome of AP is worsen by severe co-morbidities (Frey
et al., 2007; Murata et al., 2011). Therefore, we can hypothesize
that the elevation of severity and mortality with age is attributed
to co-morbidity rather than aging.
The incidence of severe AP in patients, however, showed
a continuous, linear rise between the ages of 20 and 70
(0.193%/year) of up to 16.6%. The mortality rate was 0.9%
in patients under 20 and demonstrated a continuous increase
FIGURE 9 | Meta-regression of mortality. The figure shows 43 data from 30
reports where x = age (mean), y = logit event rate: ln[p/(1-p)], and circle
diameters show the random size of each study. The meta-regression shows a
significant relationship (p = 0.022) between age and mortality.
until the age of 70. The mortality rate between 20 and 59
grew 0.086%/year and 0.765%/year between 59 and 70. Overall,
patients above 70 had a mortality rate 19 times higher than
patients under 20. The rise of mortality rate with age was thus
also confirmed.
In adults, the severity of AP clearly increases with age. With
regard to mortality, it follows a similar linear rise until 59 years;
however, after that a 9-fold change is observed in its steepness.
This result completely confirms the observation of Ranson et al.
that age is associated with a significantly increased risk of death
over 55 years (Ranson and Pasternack, 1977; Blamey et al., 1984).
Imrie et al. (1978) modified the scoring system; however, they still
considered age above 60 as a valuable parameter. Blamey et al.
(1984) evaluated a prospective study with 347 patients in a seven-
year period to simplify the system and to improve its accuracy.
With regard to age, they also found the cut-off point at 55 years.
The BISAP scoring system was established as the first
population-based prognostic scoring system in order to evaluate
the risk of in-hospital mortality prior to the onset of organ failure
(Wu et al., 2008). The CART analysis identified age above 60
years for prediction of in-hospital mortality based on parameters
collected in 2000–2001 in the first 24 h from a patient population
of 17,922 suffering from AP (Wu et al., 2008).
FIGURE 11 | Factors that may prepossess mortality and severity in AP. Our
data show that age linearly correlates to higher risk of developing severe AP.
Concerning mortality other factors may elevate the risk of decease cases
above 59 years of age.
FIGURE 10 | Forest plot results for cut-off values for mortality. Forest plot results from studies evaluating the cut-off values for mortality in acute pancreatitis with
significant results in each of four groups. All comparisons showed a significant difference.
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In summary, the predictive scoring systems correspond with
our results, which suggests that mortality rises quickly above
59 years of age. Our data suggest that other factors which are
associated with older age elevate the mortality in AP (Figure 11).
One of the candidates is definitely comorbidity. Fan et al.
in 1988 also raised the question and found that concomitant
medical and surgical diseases were responsible for the higher
in-hospital mortality rate in elderly rather that consequences
of AP (Fan et al., 1988). However, they also observed a higher
incidence of not local, but systemic complications in older age.
They concluded that, if concomitant diseases were ignored,
the difference in mortality rate between young and elderly
disappeared (Fan et al., 1988). Charlson et al. (1994) validated
an Age-Adjusted Charlson comorbidity index (CCI) showing the
absent of age from CCI index. Forty years of age have the lowest
risk of comorbid death, moreover each decade of age over 40
adds 1 extra point to the risk which is added to the calculated
CCI score.
A currently revealed propensity score-matched analysis
examined the mortality and severity in the elderly in ABP
(Patel et al., 2018). They grouped 184,763 patients in two age
groups (<65 years of age vs. ≥65 years) and found that the
index admission mortality rate for the elderly was significantly
higher (0.32% (n = 356) vs. 1.96% (n = 1473); p < 0.001).
The odds of mortality increased progressively in patients aged
75 to 84 years (OR 1.39; 95% CI: 1.06–1.82) and 85 years or
older (OR 2.21; 95% CI: 1.70, 2.86). Further, increasing age
was also associated with higher odds of severe AP (75 to 84
years: OR 1.20; 95% CI: 1.12, 1.30; 85 y or older: OR 1.28; 95%
CI: 1.17, 1.40). However, elderly patients in this analysis had
significantly higher ≥3 co-morbidities (based on an Elixhauser
score of <3 and ≥ 3) (OR 4.59; 95% CI: 4.33, 4.87; p < 0.001),
they concluded that age independently contributes to increased
mortality in ABP.
However, in order to prove the influence of comorbidity
on survivals, we wanted to extend our study with comparing
comorbidities at different age categories. Since the articles in
this study did not contain sufficient amount of information
on comorbidities we have performed a large multinational
cohort analysis on a prospective high quality database (Szakács
et al., 2018). The analysis of a total of 1,203 patients showed
that severe comorbidities (CCI≥3) predict mortality (OR =
4.48; CI: 1.57–12.80) much better than age, suggesting that
comorbidity is an important additional predictor for mortality.
More details of this investigation can be found in the forthcoming
article in Frontiers Physiological Sciences entitled: “Aging and
comorbidities in acute pancreatitis II: A cohort-analysis based
on 1 203 prospectively collected cases from 12 countries”
(DOI: 10.3389/fphys.2018.01776).
Strengths and Limitations
Strength 1 This systematic review and meta-analysis is based
on a database which is at least 10 times greater in volume than
the database used to develop the largest scoring system
Strength 2 Patients were included independently of etiologies,
nationalities, severities and ages, without any limitations in
this study.
Strength 3 Aging has serious impact on the healthcare
systems worldwide; therefore, scientists’ attention must focus
on geriatrics.
Limitation 1 In most of the articles, the age of the patients
was published in median, mean or IQR; therefore, distortion
was alerted.
Limitation 2 The severity scoring guidelines have changed
considerably over the years; therefore, there might be cases in
which severities have been misclassified in the studies under
analysis compared to our current knowledge.
Limitation 3 The co-morbidities of patients involved in
the analysis are unknown; therefore, the decisive question
as to whether age or age-associated co-morbidity plays an
aggravating role remains unanswered in this meta-analysis.
Limitation 4 The large variety of studies caused high
heterogeneity which may indicate hidden distorting factors in
this analysis.
Limitation 5 We could not explain the reason why the
mortality of the 50–59-year age group is lower than that of
the 40–49-year age group. Therefore, it cannot exclude the
possibility that the mortality rate is monophasic and the cut
off A70 is better than the cut off of 59.
CONCLUSIONS
In conclusion, our analysis shows that age has an effect
on AP. Both severity and mortality rise linearly, however
the rate of elevation in mortality is 9 times higher above
59 than below. Our results rise an important question
whether a restorative role is played by aging or other factors
like co-morbidity.
CORE TIP
There has been a dramatic increase in life expectancy over
the last few centuries. In addition, the incidence rate of
one of the most common gastrointestinal disorders, acute
pancreatitis (AP), is also growing. Here we provide a detailed
mathematical analysis of the effects of aging on AP. Our data
clearly shows that (1) younger age has a protective effect in
AP, (2) aging raises both the severity and mortality of AP,
and, importantly, (3) the mortality rate for patients above
59 years rises with 9 times greater intensity than that in
younger patients.
AUTHOR’S NOTE
The results of this article suggested clearly that additional
factors play a crucial role in mortality above 59 years of
age (Figures 7, 11). There is a Part II of this publication in
which a detailed analysis of a 1,203 prospectively collected
cases showed that comorbidity is the key factor (Figure 5
- https://www.frontiersin.org/articles/10.3389/fphys.2018.01776/
full; doi: 10.3389/fphys.2018.01776).
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